Products
Research Areas
COVID-19
Resources
Login
Quick Order
Cart
Login
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.


Fields marked with a * are required.

Login
Quick Order
Contact Us

Locations


Orders Processing,
Shipping & Receiving,
Warehouse

2 Shaker Rd Suites
B001/B101
Shirley, MA 01464


Production Lab

Floor 6, Suite 620
20700 44th Avenue W
Lynnwood, WA 98036

Telephone Numbers



Tel: +1 (206) 374-1102
Fax: +1 (206) 577-4565

Contact Us



Additional Contact Details

Login
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.


Fields marked with a * are required.

Login
Quick Order

F9 / Factor IX

coagulation factor IX

F9 / Factor IX is a vitamin K-dependent coagulation factor IX that circulates in the blood as an inactive zymogen. This factor is converted to an active form by factor XIa, which excises the activation peptide and thus generates a heavy chain and a light chain held together by one or more disulfide bonds. The role of this activated factor IX in the blood coagulation cascade is to activate factor X to its active form through interactions with Ca+2 ions, membrane phospholipids, and factor VIII. Alterations of this gene, including point mutations, insertions and deletions, cause factor IX deficiency, which is a recessive X-linked disorder, also called hemophilia B or Christmas disease.

Gene Name: coagulation factor IX
Family/Subfamily: Protease , Serine S1
Synonyms: F9, Christmas Disease, Coagulation factor IX, Factor IX Deficiency, FIX, HEMB, F9 p22, Factor 9, Factor IX, Factor IX F9, FIX F9, Haemophilia B, THPH8, Christmas factor, Hemophilia B, PTC, Serine protease
Target Sequences: NM_000133 NP_000124.1 P00740

Publications (4)

1
Targeted introduction and effective expression of hFIX at the AAVS1 locus in mesenchymal stem cells. Li SJ, Luo Y, Zhang LM, Yang W, Zhang GG. Molecular medicine reports. 2017 March;15:1313-1318. [Full Text Article] [PubMed:28112377] [PMC:PMC5367337]
2
Preclinical development of plant-based oral immune modulatory therapy for haemophilia B. Aparajitha Srinivasan, Roland W Herzog, Imran Khan, Alexandra Sherman, Thais Bertolini, Tung Wynn, Henry Daniell. Plant biotechnology journal. 2021 Oct;;19:1952-1966. [Full Text Article] [PubMed:33949086] [PMC:PMC8486253]
3
A novel next-generation FVIIIa mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: Results from safety studies in cynomolgus monkeys. Brian Lauritzen, Mads Bjelke, Olle Björkdahl, Esther Bloem, Kevin Keane, Marianne Kjalke, Marie Rossen, Solvej Lund Lippert, Karin Nana Weldingh, Mikala Skydsgaard, Stine Kjellev. Journal of thrombosis and haemostasis : JTH. 2022 June;20:1312-1324. [Full Text Article] [PubMed:35191180] [PMC:PMC9314625] Related Antibodies: LS-B7226.
4
A lipoprotein receptor cluster IV mutant preferentially binds amyloid- beta and regulates its clearance from the mouse brain. Sagare AP, Bell RD, Srivastava A, Sengillo JD, Singh I, Nishida Y, Chow N, Zlokovic BV. The Journal of biological chemistry. 2013 May;288:15154-66. [Full Text Article] [PubMed:23580652] [PMC:PMC3663536] Related Antibodies: LS-C23381.
more

Your search did not match any products.


If you do not find the reagent or information you require, please contact Customer.Support@LSBio.com to inquire about additional products in development.

PLEASE NOTE

For RESEARCH USE ONLY. Intended for use by laboratory professionals. Not intended for human diagnostic or therapeutic purposes.

The data on this page has been compiled from LifeSpan internal sources, the National Center for Biotechnology Information (NCBI), and The Universal Protein Resource (UniProt).